Food, Drugs, Healthcare, Life Sciences

The healthcare and life sciences landscape is constantly evolving as organisations strive to harness rapid technological advances.

The Supreme Court of Appeals of West Virginia declined to decide whether West Virginia allows for public nuisance claims against distributors of prescription opioids.

On June 11, 2025, was published in the DOF the "AGREEMENT recognizing as equivalent the requirements established in the Health Regulation and the technical evaluation procedures...

On June 8, 2012, Genentech’s lawsuit seeking a declaration that US Patent No. 6,733,752 was invalid and not-infringed by Genentech’s trastuzumab product (HERCEPTIN).

Health Canada specifically contemplates certain proteins as SEBs in its Guidance, although Health Canada has not limited SEBs to only particular classes of drugs.

On May 23, 2012, the Federal Court held that Merck Frosst Canada Ltd. ("Merck") is liable to Apotex Inc. ("Apotex") for damages under section 8 of the Patented Medicines (Notice of Compliance) Regulations (the "Regulations"), but exercised its discretion to reduce the amount of compensation payable based on a defence of ex turpi causa.

The healthcare and life sciences landscape is constantly evolving as organisations strive to harness rapid technological advances.

The "One Big Beautiful Bill Act" (H.R. 1), currently under consideration in the Senate, proposes sweeping changes to Affordable Care Act (ACA) Marketplace enrollment and operations.

On June 25, 2025, Kashiv BioSciences announced positive topline results from its confirmatory Phase 3 trial of ADL-018, a proposed biosimilar to XOLAIR® (omalizumab), in patients with chronic spontaneous urticaria.

The "One Big Beautiful Bill Act" (H.R. 1), currently under consideration in the Senate, proposes sweeping changes to Affordable Care Act (ACA) Marketplace enrollment and operations.

On June 18, 2025, the U.S. Food and Drug Administration ("FDA") announced an immediate review of new clinical trials that export American citizens' biological materials to countries of concern, such as China, for genetic engineering...

On June 25, 2025, Kashiv BioSciences announced positive topline results from its confirmatory Phase 3 trial of ADL-018, a proposed biosimilar to XOLAIR® (omalizumab), in patients with chronic spontaneous urticaria.